Rocco J Cannistraro1, James F Meschia2. 1. From the Department of Neurology (RJC, JFM), Mayo Clinic in Florida, 4500 San Pablo Road, Jacksonville, FL, 32256, USA. 2. From the Department of Neurology (RJC, JFM), Mayo Clinic in Florida, 4500 San Pablo Road, Jacksonville, FL, 32256, USA. meschia.james@mayo.edu.
Abstract
PURPOSE OF REVIEW: This review highlights current management of patients with concomitant cerebral amyloid angiopathy (CAA) and atrial fibrillation (AF). We review quantifying risk of ischemic and hemorrhagic stroke as well as treatments to minimize future risk. RECENT FINDINGS: Ischemic stroke risk in AF can be quantified by CHA2DS2-VASc and assessing left atrial echocardiographic characteristics. Patients deemed not low risk by CHA2DS2-VASC should be anticoagulated. CAA increases intracranial hemorrhage risk. CAA biomarkers include cortical microbleeds (CMBs), cortical superficial siderosis (cSS), convexal subarachnoid hemorrhage (cSAH), and lobar intracerebral hemorrhage (ICH). CAA with prior lobar ICH has an annual recurrence rate of 8.9%. CAA with cSAH carries an even higher annual lobar ICH risk of 19%. CMBs are associated with a dose-dependent risk of ICH, which rises with OACs. In patients with AF, antithrombotics should be avoided in CAA with predominant ICH, cSS, or cSAH features. Those with ≥ 2 CMB require in-depth risk-benefit analysis using a multidisciplinary approach.
PURPOSE OF REVIEW: This review highlights current management of patients with concomitant cerebral amyloid angiopathy (CAA) and atrial fibrillation (AF). We review quantifying risk of ischemic and hemorrhagic stroke as well as treatments to minimize future risk. RECENT FINDINGS:Ischemicstroke risk in AF can be quantified by CHA2DS2-VASc and assessing left atrial echocardiographic characteristics. Patients deemed not low risk by CHA2DS2-VASC should be anticoagulated. CAA increases intracranial hemorrhage risk. CAA biomarkers include cortical microbleeds (CMBs), cortical superficial siderosis (cSS), convexal subarachnoid hemorrhage (cSAH), and lobar intracerebral hemorrhage (ICH). CAA with prior lobar ICH has an annual recurrence rate of 8.9%. CAA with cSAH carries an even higher annual lobar ICH risk of 19%. CMBs are associated with a dose-dependent risk of ICH, which rises with OACs. In patients with AF, antithrombotics should be avoided in CAA with predominant ICH, cSS, or cSAH features. Those with ≥ 2 CMB require in-depth risk-benefit analysis using a multidisciplinary approach.
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Christopher V DeSimone; Jonathan Graff-Radford; Majd A El-Harasis; Alejandro A Rabinstein; Samuel J Asirvatham; David R Holmes Journal: J Am Coll Cardiol Date: 2017-08-29 Impact factor: 24.094
Authors: David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy Journal: J Am Coll Cardiol Date: 2014-07-08 Impact factor: 24.094
Authors: Martin J O'Donnell; John W Eikelboom; Salim Yusuf; Hans-Christoph Diener; Robert G Hart; Eric E Smith; David J Gladstone; Mukul Sharma; Rafael Dias; Greg Flaker; Alvaro Avezum; Jun Zhu; Gayle Lewis; Stuart Connolly Journal: Am Heart J Date: 2016-04-17 Impact factor: 4.749
Authors: Abby Keable; Kate Fenna; Ho Ming Yuen; David A Johnston; Neil R Smyth; Colin Smith; Rustam Al-Shahi Salman; Neshika Samarasekera; James A R Nicoll; Johannes Attems; Rajesh N Kalaria; Roy O Weller; Roxana O Carare Journal: Biochim Biophys Acta Date: 2015-08-29
Authors: Duncan Wilson; Gareth Ambler; Clare Shakeshaft; Martin M Brown; Andreas Charidimou; Rustam Al-Shahi Salman; Gregory Y H Lip; Hannah Cohen; Gargi Banerjee; Henry Houlden; Mark J White; Tarek A Yousry; Kirsty Harkness; Enrico Flossmann; Nigel Smyth; Louise J Shaw; Elizabeth Warburton; Keith W Muir; Hans Rolf Jäger; David J Werring Journal: Lancet Neurol Date: 2018-05-16 Impact factor: 59.935
Authors: Robert C Ward; Jonathan Graff-Radford; Shiva Ponamgi; Stephen English; Alayna Meskill; Apurva B Challa; David O Hodge; Joshua P Slusser; Alejandro A Rabinstein; Samuel J Asirvatham; David Holmes; Christopher V DeSimone Journal: Proc (Bayl Univ Med Cent) Date: 2021-12-28
Authors: Ulf R Jensen-Kondering; Caroline Weiler; Patrick Langguth; Naomi Larsen; Charlotte Flüh; Gregor Kuhlenbäumer; Olav Jansen; Nils G Margraf Journal: J Neurol Date: 2020-07-08 Impact factor: 4.849
Authors: Lindsey R Mitrani; Jeffeny De Los Santos; Elissa Driggin; Rebecca Kogan; Stephen Helmke; Jeff Goldsmith; Angelo B Biviano; Mathew S Maurer Journal: Amyloid Date: 2020-08-19 Impact factor: 7.141